Assetmark, Inc Biocryst Pharmaceuticals Inc Transaction History
Assetmark, Inc
- $45.6 Billion
- Q3 2025
A detailed history of Assetmark, Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Assetmark, Inc holds 3,623 shares of BCRX stock, worth $24,491. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,623
Previous 3,445
5.17%
Holding current value
$24,491
Previous $30,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding BCRX
# of Institutions
317Shares Held
201MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$139 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$135 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$57.5 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$57.2 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$38.6 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.26B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...